InvestorsHub Logo
Followers 834
Posts 120143
Boards Moderated 17
Alias Born 09/05/2002

Re: flatlander_60048 post# 5265

Thursday, 09/01/2011 9:13:03 AM

Thursday, September 01, 2011 9:13:03 AM

Post# of 20689
MYL’s Copaxone ANDA is unlikely to be approved by the FDA, IMO. Even if MYL’s ANDA is approved, MNTA’s 50/50 Copaxone profit split with NVS remains unchanged.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”